California is currently home to 5602 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Platelet Rich Plasma Testis Treatment for Infertile Men
Recruiting
Investigate the effect of intratesticular injection of autologous platelet rich plasma (PRP) on sperm retrieval rates and IVF outcomes in infertile men who already underwent a negative sperm retrieval. Currently, there is no alternative treatment after failed TESE. Prior series suggest that intratesticular PRP injections may improve TESE outcomes. We hope to determine whether PRP is an effective treatment for this patient population.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Stanford Urology Clinic, Stanford, California
Conditions: Male Infertility, Nonobstructive Azoospermia, Azoospermia
Prostate Stimulation for Sexual Dysfunction
Recruiting
The purpose of this study is to use a device to stimulate the prostate with a goal of helping improve symptoms in men with sexual dysfunction.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Stanford Healthcare, Stanford Hospital, Stanford, California
Conditions: Sexual Dysfunction, Erectile Dysfunction, Delayed Ejaculation, Anorgasmia
Incremental Hemodialysis for Veterans in the First Year of Dialysis (IncHVets)
Recruiting
In this pragmatic clinical trial, which will dovetail with Veterans' routine outpatient dialysis clinic visits in six VA medical centers, the investigators will study 252 Veterans with kidney disease who need to start dialysis treatment. If a Veteran is eligible for the study by making enough residual urine, he/she will have a 50% chance to be offered the usual three-times-per-week dialysis vs. twice-per-week dialysis that is gradually increased to three-times per- week over one year. The invest... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California
Conditions: Chronic Kidney Disease (CKD) Stage 5, Kidney Dysfunction Requiring Dialysis (KDRD), Dialysis Dependency
Use of CereGate Therapy for Freezing of Gait in PD
Recruiting
A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson's Disease.
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
05/28/2025
Locations: Kaiser Permanente, KPNC Comprehensive Movement Disorders Program, Redwood City, California
Conditions: Parkinson Disease, Freezing of Gait, Deep Brain Stimulation
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Recruiting
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Gender:
ALL
Ages:
30 years and below
Trial Updated:
05/28/2025
Locations: Lucile Packard Childrens Hospital - Stanford University, Palo Alto, California
Conditions: Lymphoma, Non-Hodgkin, Hodgkin Disease
TReatment for ImmUne Mediated PathopHysiology
Recruiting
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
05/28/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy
Recruiting
The objective is to evaluate the potential effect of exposure to dupilumab in pregnancy compared to the primary comparison group of disease-matched pregnant women who are not exposed to dupilumab, and the secondary comparison group of healthy pregnant women. The primary outcome of the study is major structural defects, and the secondary outcomes of the study are spontaneous abortion/miscarriage, stillbirth, elective termination/abortion, premature delivery, small for gestational age, pattern of... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Regeneron Research Site, La Jolla, California
Conditions: Atopic Dermatitis (AD), Asthma
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
Recruiting
To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: University of CA Davis Medical Center, Sacramento, California
Conditions: Burns
A Trial of Centanafadine Efficacy and Safety in Adults With Attention-deficit/Hyperactivity Disorder and Comorbid Anxiety
Recruiting
Phase 3b, Randomized, Double-blind, 8-week, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Centanafadine Once Daily Extended-release Capsules for the Treatment of Adults with Attention-deficit/Hyperactivity Disorder and Comorbid Anxiety
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/27/2025
Locations: Clinical Research Site #011 - NRC Research Institute, Orange, California
Conditions: ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
MAGIC Ruxolitinib for aGVHD
Recruiting
This clinical trial will study ruxolitinib-based treatment of acute graft-versus-host-disease (GVHD) that developed following allogeneic hematopoietic cell transplant. Acute GVHD occurs when donor cells attack the healthy tissue of the body. The most common symptoms are skin rash, jaundice, nausea, vomiting, and/or diarrhea. The standard treatment for GVHD is high dose steroids such as prednisone or methylprednisolone, which suppresses the donor cells, but sometimes there can be either no respon... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: City of Hope Comprehensive Cancer Center, Duarte, California
Conditions: Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Recruiting
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Gender:
ALL
Ages:
Between 13 years and 90 years
Trial Updated:
05/27/2025
Locations: City of Hope, Duarte, California
Conditions: B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Burkitt Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Non Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
Recruiting
This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects will be randomized 2:1 into one of two groups between 2-3 months post-transplant. Seventy participants will be placed into an observational group and will remain on their current post-transplant medications. The duration of the study fro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: University of California, San Francisco (Site #: 71108), San Francisco, California
Conditions: Liver Transplant